Topoisomerase I inhibitors: Selectivity and cellular resistance

Drug Resistance Updates

Volumn 2, Issue 5, 1999, Pages 307-318

  Pommier, Yves ^a   Pourquier, Philippe ^a   Urasaki, Yoshimasa ^a   Wu, Jiaxi ^a   Laco, Gary S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIHYDRO 2,3 DIMETHOXY 6 METHYL 8,9 METHYLENEDIOXY 5,11 DIOXO 11H INDENO[1,2 C]ISOQUINOLINE; 6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A][PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; DRUG METABOLITE; EXATECAN; INTOPLICINE; IRINOTECAN; LURTOTECAN; RUBITECAN; TOPOTECAN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER; CANCER RESISTANCE; CELL CYCLE; CLINICAL TRIAL; DNA REPAIR; DRUG DISTRIBUTION; DRUG INACTIVATION; DRUG METABOLISM; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG UPTAKE; ENZYME MODIFICATION; HUMAN; LUNG SMALL CELL CANCER; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW;

EID: 0033208192     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.1999.0102     Document Type: Article

References (119)

1. Gupta M., Fujimori A., Pommier Y. Eukaryotic DNA topoisomerases I. Biochim Biophys Acta. 1262:1995;1-14.
2. Wang J. C. DNA topoisomerases. Annu Rev Biochem. 65:1996;635-692.
3. Champoux J. J. Domains of human topoisomerase I and associated functions. Prog Nucleic Acids Res Mol Biol. 60:1998;111-132.
4. Redinbo M. R., Champoux J. J., Hol W. G. Structural insights into the function of type IB topoisomerases. Curr Opin Struct Biol. 9:1999;29-36.
5. Pommier Y., Pourquier P., Fan Y., Strumberg D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim Biophys Acta. 1400:1998;83-105.
6. Chen A. Y., Liu L. F. DNA Topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol. 94:1994;194-218.
7. Pommier Y., Leteurtre F., Fesen M. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest. 12:1994;530-542.
8. Pommier Y., Fujimori A., Hoki Y., Gupta M., Gariboldi M. DNA topoisomerase I inhibitors and multidrug resistance. Gupta S., Tsuruo T., Multidrug resistance in cancer cells. 1996;119-135 John Willey, Oxford.
9. Larsen A. K., Skladanowski A. Cellular resistance to topoisomerase I-targeted druugs: from drug uptake to cell death. Biochim Biophys Acta. 1400:1998;257-274.
10. Benedetti P., Benchokroun Y., Houghton P. J., Bjornsti M-A. Analysis of camptothecin resistance in yeast: relevance to cancer therapy. Drug Resist Updates. 1:1998;176-183.
11. Pourquier P., Jensen A. D., Gong S. S., Pommier Y., Rogler C. E. Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro. Nucleic Acids Res. 27:1999;1919-1923.
12. Wu J., Liu L. F. Processing of topoisomerase I cleavable complexes into DNA damage by transcription. Nucleic Acids Res. 25:1997;4181-4186.
13. Pommier Y. Topoisomerase inhibitors: Why develop new ones. Opinion in Oncologic, Endocrine & Metabolic Investigational Drugs. 1:1999;168-169.
14. Poddevin B., Riou J-F., Lavelle F., Pommier Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60475) a new antitumor agent in early clinical trials. Mol Pharmacol. 44:1993;767-774.
15. Bailly C., Riou J-F., Colson P., Houssier C., Rodriguez-Pereira E., Prudhomme M. DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry. 36:1997;3917-3929.
16. Strumberg D., Pommier Y., Paull K., Jayaraman M., Nagafuji P., Cushman M. Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons. J Med Chem. 42:1999;446-457.
17. Bailly C., Dassonneville L., Colson P. Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents. Cancer Res. 59:1999;2853-2860.
18. Tanizawa A., Fujimori A., Fujimori Y., Pommier Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst. 86:1994;836-842.
19. Tanizawa A., Kohn K. W., Kohlhagen G., Leteurtre F., Pommier Y. Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives. Biochemistry. 34:1995;7200-7206.
20. Potter P. M., Wolverton J. S., Morton C. L., Wierdl M., Danks M. K. Cellular localization domains of a rabbit and a human carboxylesterase: influence on irinotecan (CPT-11) metabolism by the rabbit enzyme. Cancer Res. 58:1998;3627-3632.
21. Morton C. L., Wadkins R. M., Danks M. K., Potter P. M. The anticancer prodrug CPT-11 is a potent inhibitor of acetylcholinesterase but is rapidly catalyzed to SN-38 by butyrylcholinesterase. Cancer Res. 59:1999;1458-1463.
22. Haaz M. C., Rivory L. P., Riche C., Robert J. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms. Naunyn Schmiedebergs Arch Pharmacol. 356:1997;257-262.
23. Niimi S., Nakagawa K., Sugimoto Y. Mechanism of cross-resistane to a camptothecin analogue (CPT-11) in a human ovarian cancer cell line selected by cisplatin. Cancer Res. 52:1992;328-333.
24. Kanzawa F., Sugimoto Y., Minato K. Establishement of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance. Cancer Res. 50:1990;5919-5924.
25. Nagai S., Yamauchi M., Andoh T. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin). J Surg Oncol. 59:1995;116-124.
26. Saijo N., Nishio K., Kubota N. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials. Cancer Chemother Pharmacol. 34 Suppl:1994;S112-117.
27. Danks M. K., Morton C. L., Pawlik C. A., Potter P. M. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res. 58:1998;20-22.
28. Rivory L. P., Riou J-F., Haaz M. C. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res. 56:1996;3689-3694.
29. Rosing H., van Zoomeren D. M., Doyle E., Bult A., Beijinen J. H. O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyltopotecan. Anticancer Drugs. 9:1998;587-592.
30. Gupta E., Lestingi T. M., Mick R., Ramirez J., Vokes E. E., Ratain M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54:1994;3723-3725.
31. Rivory L. P., Robert J. Identification and kinetics of a beta-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol. 36:1995;176-179.
32. Iyer L., King C. D., Whitington P. F. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 101:1998;847-854.
33. Lyer L., King C. D., Whitington P. F. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest. 101:1998;847-854.
34. Wasserman E., Myara A., Lokiec F. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol. 8:1997;1049-1051.
35. Takahashi T., Fujiwara Y., Yamakido M., Katoh O., Watanabe H., Mackenzie P. I. The role of glucuronidation in 7-ethyl-10-hydroxycamptothecin resistance in vitro. Jpn J Cancer Res. 88:1997;1211-1217.
36. Hendricks C. B., Rowinsky E. K., Grochow L. B., Donchower R. C., Kaufmann S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res. 52:1992;2268-2278.
37. Ambudkar S. V., Lelong I. H., Zhang J., Cardarelli C. O., Gottesman M. M., Pastan I. Partial purification and reconstitution of the human multidrug-resistance pump: characterization of the drug-stimulatable ATP hydrolysis. Proc Natl Acad Sci USA. 89:1992;8472-8476.
38. Hoki Y., Fujimori A., Pommier Y. Differential cytotoxcity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines. Cancer Chemother Pharmacol. 40:1997;433-438.
39. Mattern M. R., Hofman G. A., Polsky R. M., Funk L. R., McCabe F. L., Johnson R. K. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res. 5:1993;467-474.
40. Jansen W. J. M., Hulscher T. M., van Ark-Otte J., Giaconne G., Pinedo H. M., Boven E. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Br J Cancer. 77:1998;359-365.
41. Chen Z-S., Furukawa T., Sumizawa T. ATP-dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 55:1999;921-928.
42. Yang C-H. J., Horton J. K., Cowan K. H., Schneider E. Cross-resistance to camptothecin analogues in mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations. Cancer Res. 55:1995;4004-4009.
43. Ma J., Maliepaard M., Nooter K. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer. 77:1998;1645-1652.
44. Brangi M., Litman T., Ciotti G. Camptothecin resistance: role of the ABC half-transporter, MXR, and potential for glucuronidation in MXR-expressing cells. Cancer Res. 1999.
45. Miyake K., Mickley L., Litman T. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology of ABC transport genes. Cancer Res. 59:1999;8-13.
46. Maliepaard M., van Gastelen M. A., de Jong L. A. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line [In Process Citation]. Cancer Res. 59:1999;4559-4563.
47. Redinbo M. R., Stewart L., Kuhn P., Champoux J. J., Hol W. G. J. Crystal structure of human topoisomerase I in covalent and noncovalent complexes with DNA. Science. 279:1998;1504-1513.
48. Stewart L., Redinbo M. R., Qiu X., Hol W. G. J., Champoux J. J. A model for the mechanism of human topoisomerase I. Science. 279:1998;1534-1541.
49. Stewart L., Ireton G. C., Champoux J. J. Reconstitution of human topoisomerase I by fragment complementation. J Mol Biol. 269:1997;355-372.
50. Simmons D. T., Melendy T., Usher D., Stillman B. Simian virus 40 large T antigen binds to topoisomerase I. Virology. 222:1996;365-374.
51. Pommier Y., Kohlhagen G., Wu C., Simmons D. T. Mammalian DNA topoisomerase I activity and poisoning by camptothecin are inhibited by simian virus 40 large T antigen. Biochemistry. 1998.
52. Merino A., Madden K. R., Lane W. S., Champoux J. J., Reinberg D. DNA topoisomerase I is involved in both repression and activation of transcription. Nature. 365:1993;227-232.
53. Bharti A. K., Olson M. O. J., Kufe D. W., Rubin E. H. Identification of a nucleophilin binding site in human topoisomerase I. J Biol Chem. 271:1996;1993-1997.
54. Haluska P. J., Saleem A., Rasheed Z. Interaction between human topoisomerase I and a novel RING finger/arginine-serine protein. Nucleic Acids Res. 27:1999;2538-2544.
55. Kikuchi A., Miyaike M. Expression of human type I and II DNA topoisomerases and their derivatives in Escherichia coli. Andoh T., Ikeda H., Oguro M., Molecular biology of DNA topoisomerases and its application to chemotherapy. 1993;121-130 CRC Press, Boca Raton.
56. Pommier Y., Kohlhagen G., Kohn F., Leteurtre F., Wani M. C., Wall M. E. Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci USA. 92:1995;8861-8865.
57. Jaxel C., Capranico G., Kerrigan D., Kohn K. W., Pommier Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J Biol Chem. 266:1991;20418-20423.
58. Fan Y., Kohn K. W., Shi L. M., Weinstein J. N., Pommier Y. Molecular modeling studies of the DNA topoisomerase I ternary complex with camptothecin. J Med Chem. 41:1998;2216-2226.
59. Komatani H., Morita M., Sakaizumi N. A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I. Cancer Res. 59:1999;2701-2708.
60. Andoh T., Ishii K., Suzuki Y. Characterization of a mammalian mutant with a camptothecin resistant DNA topoisomerase I. Proc Natl Acad Sci USA. 84:1987;5565-5569.
61. Tan K. B., Mattern M. R., Eng W-K., McCabe F. L., Johnson R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J Natl Cancer Inst. 81:1989;1732-1735.
62. Sugimoto Y., Tsukahara S., Oh-hara T., Isoe T., Tsuruo T. Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res. 50:1990;6925-6930.
63. Woessner R. D., Eng W-K., Hofmann G. A. Camptothecin hyper-resistant P388 cells: drug-dependent reduction in topoisomerase I content. Oncol Res. 4:1993;481-488.
64. Chang J-Y., Dethlefsen L. A., Barley L. R., Zhou B. S., Cheng Y-C. Characterization of camptothecin-resistant chinese hamster lung cells. Biochem Pharmacol. 43:1992;2443-2452.
65. Fujimori A., Harker W. G., Kohlhagen G., Hoki Y., Pommier Y. Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell resistant to camptothecin. Cancer Res. 55:1995;1339-1346.
66. Eng W. K., McCabe F. L., Tan K. B. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol. 38:1990;471-480.
67. Fujimori A., Hoki Y., Popescu N., Pommier Y. Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells. Oncol Res. 1996;295-301.
68. Madelaine I., Prost S., Naudin A., Riou G., Lavelle F., Riou J-F. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem Pharmacol. 45:1993;339-348.
69. Gupta R. S., Gupta R., Eng B. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res. 48:1988;6404-6410.
70. Oguro M., Seki Y., Okada K., Andoh T. Collateral drug sensitivity induced in CPT-11 (a novel derivative of camptothecin)-resistant cell lines. Biomed Pharmacother. 1990;209-216.
71. Tan K. B., Dorman T. E., Falls K. M. Topoisomerase II-alpha and topoisomerase II-beta genes: characterization and mapping to human chromosomes 17 and 3, respectively. Cancer Res. 52:1992;231-234.
72. Sorensen M., Sehested M., Jensen P. B. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer. 72:1995;399-404.
73. Goldwasser F., Shimizu T., Jackman J. Correlations between S- and G2-phase arrest and cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 56:1996;4430-4437.
74. Nitiss J. L., Wang J. C. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA. Mol Pharmacol. 50:1996;1095-1102.
75. Morris E. J., Geller H. M. Induction of neuronal apoptosis by camptothecin, an inhibitor of DNA topoisomerase-I: evidence for cell cycle-independent toxicity. J Cell Biol. 134:1996;757-770.
76. Borovitskaya A. E., D'Arpa P. Replication-dependent and -independent camptothecin cytotoxicity of seven human colon tumor cell lines. Oncol Res. 10:1998;271-276.
77. Pourquier P., Ueng L-M., Kohlhagen G. Effects of uracil incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem. 272:1997;7792-7796.
78. Pourquier P., Pilon A., Kohlhagen G., Mazumder A., Sharma A., Pommier Y. Trapping of mammalian topoisomerase I and recombinations induced by damaged DNA containing nicks or gaps: importance of DNA end phosphorylation and camptothecin effects. J Biol Chem. 272:1997;26441-26447.
79. Pourquier P., Bjornsti M-A., Pommier Y. Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct, 1, N6-ethenoadenine. J Biol Chem. 273:1998;27245-27249.
80. Pommier Y., Kohlhagen G., Pourquier P., Sayer J. M., Kroth H., Jerina D. M. Induction of topoisomerase I-mediated DNA cleavage and recombinations by benzo[a]pyrene diol epoxide-DNA adducts. Proc Natl Acad Sci USA. 1999;in press.
81. Desai S. D., Liu L. F., Vazquez-Abad D., D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem. 272:1997;24159-24164.
82. Beidler D. R., Cheng Y-C. Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity. Mol Pharmacol. 47:1995;907-914.
83. Yang S-W., Burgin A. B., Huizenga B. N., Robertson C. A., Yao K. C., Nash H. A. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. Proc Natl Acad Sci USA. 93:1996;11534-11539.
84. Pouliot J. J., Yao K. C., Robertson C. A., Nash H. A. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topo I covalent complexes. Science. 1999;in press.
85. Sastry S., Ross B. M. Mechanisms for the processing of a prozen topoisomerase-DNA conjugate by human cell-free extracts. J Biol Chem. 273:1998;9942-9950.
86. Squires S., Ryan A. J., Strutt H. L., Johnson R. T. Hypersensitivity of Cockayne's syndrome cells to camptothecins is associated with the generation of abnormally high levels of double strand breaks in nascent DNA. Cancer Res. 53:1993;2012-2019.
87. Fujimori A., Gupta M., Hoki Y., Pommier Y. Acquired resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair. Mol Pharmacol. 50:1996;1472-1478.
88. Shao R-G., Cao C-X., Zhang H., Kohn K. W., Wold M. S., Pommier Y. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA: DNA-PK complexes. EMBO J. 18:1999;1397-1406.
89. Eng W. K., Faucette L., Johnson R. K., Sternglanz R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol Pharmacol. 34:1988;755-760.
90. Nitiss J., Wang J. C. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci USA. 85:1988;7501-7505.
91. Smith P. J., Makinson T. A., Watson J. V. Enhanced sensitivity to camptothecin in ataxia telangiectasia cells and its relationship with the expression of DNA topoisomerase I. Int J Radiat Biol. 55:1989;217-231.
92. Jones N. J., Ellard S., Waters R., Parry E. M. Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells. Carcinogenesis. 14:1993;2487-2494.
93. Tsao Y-P., D'Arpa P., Liu L. F. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res. 52:1992;1823-1829.
94. Goldwasser F., Bae I. S., Torres K., Pommier Y. Topoisomerase I-related parameters and camptothecin activity in the colon cell lines from the National Cancer Institute anticancer screen. Cancer Res. 55:1995;2116-2121.
95. Gupta M., Fan S., Zhan Q., Kohn K. W., O'Connor P. M., Pommier Y. Inactivation of p53 increases the cytotoxicity of camptothecin in human colon HCT116 and breast MCF-7 cancer cells. Clin Cancer Res. 3:1997;1653-1660.
96. Shao R-G., Cao C-X., Shimizu T., O'Connor P., Kohn K. W., Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53. Cancer Res. 57:1997;4029-4035.
97. Shimizu T., Cao C-X., Shao R-G., Pommier Y. Lamin B phosphorylation by protein kinase Calpha and proteolysis during apoptosis in human leukemia HL60 cells. J Biol Chem. 1998;in press.
98. Samejima K., Svingen P. A., Basi G. S. Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis. J Biol Chem. 274:1999;4335-4340.
99. Nieves-Neira W., Pommier Y. Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the eight human breast cancer cell lines of the NCI anticancer drug screen: multifactorial relationship with topoisomerase I, protein kinase C, bcl-2 and caspase pathways. Int J Cancer. 82:1999;396-404.
100. Walton M. I., Whysong D., O'Connor P. M., Hockenbery D., Korsmeyer S. J., Kohn K. W. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res. 53:1993;1853-1861.
101. Rubin E., Pantazis P., Toppmeyer D., Giovanella B., Kufe D. Identification of a mutant human topoisomerase I with intact catalytic and resistance to 9-nitro-camptothecin. J Biol Chem. 269:1994;2433-2439.
102. Li X-G., Haluska P., Hsiang Y-H. Involvement of amino acids 361 to 364 of human topoisomerase I in camptothecin resistance and enzyme catalysis. Biochem Pharmacol. 53:1997;1019-1027.
103. Benedetti P., Fioranti P., Capuani L., Wang J. C. Camptothecin resistance from a single mutation changing glycine 363 of human DNA topoisomerase I to cysteine. Cancer Res. 53:1993;4343-4348.
104. Tanizawa A., Pommier Y. Topoisomerase I alteration in a camptothecin-resistant cell line derived from chinese hamster DC3F cells in culture. Cancer Res. 52:1992;1848-1854.
105. Tanizawa A., Bertrand R., Kohlhagen G., Tabuchi A., Jenkins J., Pommier Y. Cloning of Chinese Hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J Biol Chem. 268:1993;25463-25468.
106. Tamura H-O., Kohchi C., Yamada R. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res. 19:1991;69-75.
107. Kubota N., Kanzawa F., Nishio K. Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line. Biochem Biophys Res Commun. 188:1992;571-577.
108. Wang L-F., Ting C-Y., Lo C-K. Identification of mutations of DNA topoisomerase I response for camptothecin resistance. Cancer Res. 57:1997;1516-1522.
109. Knab A. M., Fertala J., Bjornsti M-A. Mechanisms of camptothecin resistance in Yeast DNA topoisomerase I mutants. J Biol Chem. 268:1993;22322-22330.
110. Beidler D. R., Chang J-Y., Zhou B-S., Cheng Y-C. Camptothecin resistance involving steps subsequent to the formation of protein-linked DNA breaks in human camptothecin-resistant KB cell lines. Cancer Res. 56:1995;345.
111. Lebel M., Leder P. A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of proliferative capacity. Proc Natl Acad Sci USA. 95:1998;13097-13102.
112. Poot M., Gollahon K. A., Rabinovitch P. S. Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum Genet. 104:1999;10-14.
113. Kraakman-van der Zwet M., Overkamp W. J., Friedl A. A. Immortalization and characterization of Nijmegen Breakage syndrome fibroblasts. Mutat Res. 434:1999;17-27.
114. Barrows L. R., Holden J. A., Anderson M., D'Arpa P. The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. Mutat Res. 408:1998;103-110.
115. Thacker J., Ganesh A. N. DNA-break repair, radioresistance of DNA synthesis, and camptothecin sensitivity in the radiation-sensitive irs mutants: comparisons to ataxia-telangiectasia cells. Mutat Res. 235:1990;49-58.
116. Caldecott K., Jeggo P. Cross-sensitivity of gamma-ray-sensitive hamster mutants to cross-linking agents. Mutat Res. 255:1991;111-121.
117. Johnson R. T., Gotoh E., Mullinger A. M. Targeting double-strand breaks to replicating DNA identifies a subpathway of DSB repair that is defective in ataxiatelangiectasia cells. Biochem Biophys Res Commun. 261:1999;317-325.
118. Chatterjee S., Cheng M-F., Trivedi D., Petzold S. J., Berger N. A. Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines. Cancer Commun. 1:1989;389-394.
119. Hinz H. R., Harris N. J., Natelson E. A., Giovanella B. C. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20-(S)-camptothecin to 9-amino-20(S)-camptothecin in humans, dogs, and mice. Cancer Res. 54:1994;3096-3100.